eMedicine Specialties > Cardiology > Valvular Heart Disease

Tricuspid Regurgitation

Author: Mary C Mancini, MD, PhD, Professor, Department of Surgery, Louisiana State University Health Sciences Center
Contributor Information and Disclosures

Updated: Jul 29, 2008

Introduction

Background

Tricuspid regurgitation may result from structural alterations of any one or all of the components of the tricuspid valve apparatus. Components include the leaflets, chordae tendinea, annulus, and papillary muscles or adjacent right ventricular (RV) muscle. The lesion may be classified as primary when it is caused by an intrinsic abnormality of the valve apparatus or as secondary when it is caused by RV dilatation.

Pathophysiology

The pathophysiology of tricuspid regurgitation focuses on the structural incompetence of the valve. The incompetent nature of the valve can result from primary structural abnormalities of the leaflets and chordae or from secondary myocardial dysfunction and dilatation.1

Tricuspid valve insufficiency due to leaflet abnormalities may be secondary to endocarditis or rheumatic heart disease. When due to the latter, it generally occurs in combination with tricuspid stenosis. Ebstein anomaly is the most common congenital form of tricuspid regurgitation.

In tricuspid regurgitation, chronic right ventricular volume overload results in right-sided congestive heart failure (CHF) manifested by hepatic congestion, peripheral edema, and ascites. For more on heart failure, see Medscape's Heart Failure Resource Center.

Frequency

United States

Incidence of tricuspid regurgitation appears to be 0.9%.

International

Incidence of tricuspid regurgitation appears to be less than 1%.

Mortality/Morbidity

The morbidity and mortality of the disease process are secondary to the underlying cause. In rheumatic disease, mortality rates with treatment are less than 3%. In Ebstein anomaly, mortality depends upon the severity of the valvular deformity and the feasibility of correction. Mortality rates with correction are approximately 10%. Tricuspid regurgitation resulting from myocardial dysfunction or dilatation has a mortality of up to 50% at 5 years.

Race

No race predilection is apparent.

Sex

No sex predilection is apparent.

Age

Ebstein anomaly can be detected at birth and during early childhood. In patients older than 15 years, the most common form of tricuspid regurgitation is rheumatic valvular disease. In the adult population, other predisposing factors, including carcinoid, bacterial endocarditis, and CHF, takes precedence.

Clinical

History

The patient with tricuspid regurgitation presents with the signs and symptoms of right-sided heart failure. The spectrum of presenting symptoms is dependent upon whether the condition is secondary to left ventricular (LV) dysfunction. If it is, dyspnea on exertion, orthopnea, and paroxysmal nocturnal dyspnea accompany ascites and peripheral edema as common presenting complaints. Exercise intolerance may also be observed. The patient rarely reports angina, which may be present in the absence of coronary artery disease secondary to RV overload and strain.2

These patients must be questioned regarding intravenous drug use, history of rheumatic fever, and febrile episodes because bacterial endocarditis is a common cause of tricuspid valvular disease.

Physical

S3 gallop is present, and the following physical findings may be found:

  • Jugular venous distention with a prominent V wave: When present, a pansystolic murmur is heard along the lower left sternal border with inspiratory accentuation.
  • Diminished peripheral pulse volume secondary to impaired forward blood flow: Patients with this sign may have relative hypotension secondary to therapeutic interventions used to decrease volume overload.
  • Pulmonary rales if the tricuspid regurgitation is associated with LV dysfunction or mitral stenosis
  • RV heave and S 4 gallop that increases with inspiration
  • Ascites
  • Peripheral edema
  • Cachexia and jaundice
  • Atrial fibrillation (For more information on atrial fibrillation, see Medscape's Atrial Fibrillation Resource Center.)
  • A high-pitched pansystolic murmur (loudest in the fourth intercostal space in the parasternal region). The murmur is usually augmented during inspiration and is reduced in intensity and duration in the standing position and during a Valsalva maneuver. A short, early diastolic flow rumble may be present due to increased flow across the tricuspid valve.

Causes

Pure tricuspid regurgitation can be caused by at least 10 conditions.

Rheumatic heart disease

  • Tricuspid regurgitation secondary to rheumatic involvement is usually associated with mitral and aortic valve pathology.1
  • The valve develops diffuse fibrous thickening without commisural fusion, fused chordae, or calcific deposits. Occasionally, the chordae may be mildly thickened by fibrous tissue.
  • Rheumatic disease is the most common cause of pure tricuspid regurgitation due to deformation of the leaflets.

Endocarditis

  • This is an important cause of tricuspid regurgitation. Precipitating factors that can contribute to infection of the valve include alcoholism, intravenous drug use, neoplasms, infected indwelling catheters, extensive burns, and immune deficiency disease.
  • The clinical presentation is often that of pneumonia from septic pulmonary emboli rather than CHF. Heart murmurs are frequently absent and blood cultures may be negative. Annular abscesses are not uncommon.

Ebstein anomaly 

  • This entity is a congenital malformation of the tricuspid valve characterized by apical displacement of the annular insertion of the septal and posterior leaflets and atrialization of a portion of the ventricular myocardium.
  • Prognosis for these patients depends upon the degree of apical displacement of the tricuspid annulus and the severity of the regurgitation.3

Prolapse (floppy, redundant)  

  • The incidence of floppy tricuspid valve varies from 0.3-3.2%.
  • The lesion appears to be associated with prolapse of the mitral valve and uncommonly occurs in an isolated fashion.
  • Histological examination of the floppy tricuspid valve shows alterations on the valve spongiosa. 

Carcinoid  

  • Pure tricuspid regurgitation can occur as part of the carcinoid heart syndrome.
  • Fibrous white plaques form on the ventricular aspect of the tricuspid valve and endocardium, causing the valve to adhere to the RV wall.
  • Proper coaptation of the leaflets does not occur during systole, resulting in tricuspid regurgitation.4

Papillary muscle dysfunction 

  • Papillary muscle dysfunction may result from necrosis (secondary to myocardial infarction), fibrosis, or infiltrative processes.
  • Although dysfunction secondary to myocardial infarction is less common than occurs with the mitral valve, the underlying cause must be determined in order to plan treatment. 

Trauma

  • Trauma to the right ventricle may damage the structures of the tricuspid valve, resulting in insufficiency of the structure.5
  • More commonly it is associated with stab wounds or projectile destruction of the valve. 

Connective-tissue diseases

  • Patients with Marfan syndrome or other connective-tissue diseases (eg, osteogenesis imperfecta, Ehlers-Danlos syndrome) may have tricuspid regurgitation.
  • Typically, dysfunction of other valves is also observed in the same patient.
  • The etiology of the regurgitation can be attributed to a floppy tricuspid valve and a mildly dilated tricuspid valve annulus.

Medications

  • Medications that act via serotoninergic pathways may cause valvular lesions similar to those observed with carcinoid.
  • Medications used to treat migraine (eg, methysergide), Parkinson disease (eg, pergolide), and obesity (eg, fenfluramine) have been associated with tricuspid regurgitation.

Anatomically normal tricuspid valve

  • A common etiology of tricuspid regurgitation is dilatation of the RV cavity.
  • The valve structures are normal; however, because of enlargement of the cavity and dilatation of the annulus, proper coaptation of the leaflets is not possible.
  • Causes of the dilatation include mitral stenosis, pulmonic stenosis or regurgitation, pulmonary hypertension, dilated cardiomyopathy, and RV failure.

More on Tricuspid Regurgitation

Overview: Tricuspid Regurgitation
Differential Diagnoses & Workup: Tricuspid Regurgitation
Treatment & Medication: Tricuspid Regurgitation
Follow-up: Tricuspid Regurgitation
References

References

  1. Frater R. Tricuspid insufficiency. J Thorac Cardiovasc Surg. Sep 2001;122(3):427-9. [Medline].

  2. Sugimoto T, Okada M, Ozaki N, et al. Long-term evaluation of treatment for functional tricuspid regurgitation with regurgitant volume: characteristic differences based on primary cardiac lesion. J Thorac Cardiovasc Surg. Mar 1999;117(3):463-71. [Medline].

  3. Khan IA. Ebstein's anomaly of the tricuspid valve with associated mitral valve prolapse. Tex Heart Inst J. 2001;28(1):72. [Medline].

  4. Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. Feb 2002;77(2):139-47. [Medline].

  5. Luo GH, Ma WG, Sun HS, et al. Correction of traumatic tricuspid insufficiency using the double orifice technique. Asian Cardiovasc Thorac Ann. Sep 2005;13(3):238-40. [Medline].

  6. Ha JW, Chung N, Jang Y, Rim SJ. Tricuspid stenosis and regurgitation: Doppler and color flow echocardiography and cardiac catheterization findings. Clin Cardiol. Jan 2000;23(1):51-2. [Medline].

  7. Shah PM, Raney AA. Tricuspid valve disease. Curr Probl Cardiol. Feb 2008;33(2):47-84. [Medline].

  8. Vlahos AP, Feinstein JA, Schiller NB, Silverman NH. Extension of Doppler-derived Echocardiographic Measures of Pulmonary Vascular Resistance to Patients with Moderate or Severe Pulmonary Vascular Disease. J Am Soc Echocardiogr. Jan 8 2008;[Medline].

  9. Anderson C, Filsoufi F, Farivar RS, Adams DH. Optimal management of severe tricuspid regurgitation in cardiac transplant recipients. J Heart Lung Transplant. Feb 2001;20(2):247. [Medline].

  10. DeLeon MA, Gidding SS, Gotteiner N, Backer CL, Mavroudis C. Successful palliation of Ebstein's malformation on the first day of life following fetal diagnosis. Cardiol Young. Oct 2000;10(4):384-7. [Medline].

  11. Filsoufi F, Anyanwu AC, Salzberg SP, et al. Long-term outcomes of tricuspid valve replacement in the current era. Ann Thorac Surg. Sep 2005;80(3):845-50. [Medline].

  12. Gatti G, Maffei G, Lusa AM, Pugliese P. Tricuspid valve repair with the Cosgrove-Edwards annuloplasty system: early clinical and echocardiographic results. Ann Thorac Surg. Sep 2001;72(3):764-7. [Medline].

  13. Abrams DJ, Kilner P, Till JA, et al. Prolapse of the antero-superior leaflet of the tricuspid valve secondary to congenital anomalies of the valvar and sub-valvar apparatus: a rare cause of severe tricuspid regurgitation. Cardiol Young. Aug 2005;15(4):417-21. [Medline].

  14. Burgess MI, Aziz T, Yonan N. Clinical relevance of subclinical tricuspid regurgitation after orthotopic cardiac transplantation. J Am Soc Echocardiogr. Feb 1999;12(2):164. [Medline].

  15. Daniels SJ, Mintz GS, Kotler MN. Rheumatic tricuspid valve disease: two-dimensional echocardiographic, hemodynamic, and angiographic correlations. Am J Cardiol. Feb 1983;51(3):492-6. [Medline].

  16. Hachiro Y, Sugimoto S, Takagi N, et al. Native valve salvage for post-traumatic tricuspid regurgitation. J Heart Valve Dis. Mar 2001;10(2):276-8. [Medline].

  17. Kanzaki H, Nakatani S, Kawada T, et al. Right ventricular dP/dt/P(max), not dP/dt(max), noninvasively derived from tricuspid regurgitation velocity is a useful index of right ventricular contractility. J Am Soc Echocardiogr. Feb 2002;15(2):136-42. [Medline].

  18. Krupa W, Kozlowski D, Derejko P, Swiatecka G. Permanent cardiac pacing and its influence on tricuspid valve function. Folia Morphol (Warsz). Nov 2001;60(4):249-57. [Medline].

  19. Kuwaki K, Morishita K, Tsukamoto M, Abe T. Tricuspid valve surgery for functional tricuspid valve regurgitation associated with left-sided valvular disease. Eur J Cardiothorac Surg. Sep 2001;20(3):577-82. [Medline].

  20. Leszek P, Zielinski T, Rozanski J, et al. Traumatic tricuspid valve insufficiency: case report. J Heart Valve Dis. Jul 2001;10(4):545-7. [Medline].

  21. Mansencal N, Mourvillier B, Schwob J, et al. Asymptomatic traumatic tricuspid regurgitation: a case report with an early diagnosis. Ann Emerg Med. Feb 2002;39(2):205. [Medline].

  22. Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation. Aug 30 2005;112(9 Suppl):I453-7. [Medline].

  23. Messing B, Porat S, Imbar T, et al. Mild tricuspid regurgitation: a benign fetal finding at various stages of pregnancy. Ultrasound Obstet Gynecol. Nov 2005;26(6):606-9; discussion 610. [Medline].

  24. Motoyoshi N, Tofukuji M, Sakurai M, et al. Cleft on tricuspid anterior leaflet. Ann Thorac Surg. Apr 2001;71(4):1350-1. [Medline].

  25. Numata S, Uemura H, Yagihara T, et al. Replacement of the morphologically tricuspid valve in children with discordant atrioventricular connections. J Heart Valve Dis. Nov 1999;8(6):649-54. [Medline].

  26. Oliver JM, Gallego P, Gonzalez A, et al. Predisposing conditions for atrial fibrillation in atrial septal defect with and without operative closure. Am J Cardiol. Jan 1 2002;89(1):39-43. [Medline].

  27. Smrcek JM, Krapp M, Axt-Fliedner R, et al. Atypical ductus venosus blood flow pattern in fetuses with severe tricuspid valve regurgitation. Ultrasound Obstet Gynecol. Aug 2005;26(2):180-2. [Medline].

  28. Tribouilloy CM, Enriquez-Sarano M, Bailey KR, et al. Quantification of tricuspid regurgitation by measuring the width of the vena contracta with Doppler color flow imaging: a clinical study. J Am Coll Cardiol. Aug 2000;36(2):472-8. [Medline].

  29. Trojnarska O, Szyszka A, Gwizdala A, et al. Adults with Ebstein's anomaly-Cardiopulmonary exercise testing and BNP levels Exercise capacity and BNP in adults with Ebstein's anomaly. Int J Cardiol. Oct 18 2005;[Medline].

  30. Yiwu L, Yingchun C, Jianqun Z, et al. Exact quantitative selective annuloplasty of the tricuspid valve. J Thorac Cardiovasc Surg. Sep 2001;122(3):611-4. [Medline].

Further Reading

Keywords

tricuspid regurgitation, tricuspid valve, leaflets, chordae tendinea, annulus, papillary muscles, adjacent right ventricular muscle, intrinsic abnormality of the valve apparatus, tricuspid insufficiency, Ebstein's anomaly, Ebstein anomaly, tricuspid stenosis, chronic right atrial overload, right-sided congestive heart failure, CHF, hepatic congestion, peripheral edema, ascites, hypoxemia, cyanosis, polycythemia, rheumatic valvular disease, carcinoid, bacterial endocarditis, Marfan syndrome, osteogenesis imperfecta, Ehlers-Danlos syndrome, porcine heterograft, rheumatic heart disease, endocarditis, papillary muscle dysfunction, connective-tissue disease, dilatation of the right ventricular cavity, mitral stenosis, pulmonic stenosis, pulmonary hypertension, dilated cardiomyopathy, right ventricular failure, left-sided heart failure, organic disease of the tricuspid valve, mitral valve disease, pulmonary hypertension, tricuspid valve endocarditis

Contributor Information and Disclosures

Author

Mary C Mancini, MD, PhD, Professor, Department of Surgery, Louisiana State University Health Sciences Center
Mary C Mancini, MD, PhD is a member of the following medical societies: American Heart Association, American Medical Association, American Thoracic Society, Association for Academic Surgery, Association for Surgical Education, International College of Surgeons, International Society for Heart and Lung Transplantation, New York Academy of Sciences, Phi Beta Kappa, and Southern Thoracic Surgical Association
Disclosure: Nothing to disclose.

Medical Editor

Martin Keane, MD, FACC, FAHA, Associate Professor, Cardiovascular Medicine Division, Department of Medicine, University of Pennsylvania School of Medicine
Martin Keane, MD, FACC, FAHA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Heart Association, American Society of Echocardiography, Pennsylvania Medical Society, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Ronald J Oudiz, MD, Director of Pulmonary Hypertension, Associate Professor, Department of Medicine, Division of Cardiology, Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA
Ronald J Oudiz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, and American Heart Association
Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Encysive Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD, E Cowles Andrus Professor of Cardiology, Professor of Medicine, Johns Hopkins University School of Medicine
Richard A Lange, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, and Association of Subspecialty Professors
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.